Edition:
United Kingdom

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

27.14USD
3:47pm GMT
Change (% chg)

$1.39 (+5.40%)
Prev Close
$25.75
Open
$25.74
Day's High
$27.55
Day's Low
$25.74
Volume
3,269
Avg. Vol
1,029
52-wk High
$48.42
52-wk Low
$16.65

Select another date:

Wed, Jan 3 2018

BRIEF-BeyondSpring Appoints Patrick Fabbio To Board As An Independent Member

* BEYONDSPRING APPOINTS LIFE SCIENCES VETERAN PATRICK FABBIO TO BOARD OF DIRECTORS AS AN INDEPENDENT MEMBER Source text for Eikon: Further company coverage:

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)

BRIEF-Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China

* BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY

BRIEF-BeyondSpring qtrly loss per share $‍0.68

* BeyondSpring reports third quarter 2017 operational and financial results

BRIEF-BeyondSpring announces first patient enrolled in China

* BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia

Select another date: